Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

RHYTHM PHARMACEUTICALS, INC. Director's Dealing 2019

Feb 15, 2019

30849_dirs_2019-02-15_feefd82a-2321-4d77-a1be-4177606294c8.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2019-02-13

Reporting Person: Stewart Murray (Chief Medical Officer)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2019-02-13 Employee Stock Option (Right to Buy) $29.78 A 60000 Acquired 2029-02-12 Common Stock (60000) Direct

Footnotes

F1: This option was granted on February 13, 2019 and the shares underlying this option vest in sixteen equal quarterly installments beginning on May 13, 2019.